Sponsor or institution

Clinical trials and research at Gruppo Italiano Malattie EMatologiche dell'Adulto

• 12Clinical trials
• 1New in 30 days
• 2Countries

Newest trials

All recruiting trials (12)

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• APL-like A Cute Myeloid Leukemia in NPM1-M mutated patients: distinctive features and early vascular events

  This observational study tests whether an APL-like appearance in NPM1-mutated AML can predict early clotting problems and vascular events.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Florence · NCT07080970

• Selinexor plus bortezomib and dexamethasone for relapsed multiple myeloma after 1–3 prior therapies

  This study will try to see how the selinexor + bortezomib + dexamethasone (SVd) combination works and how safe it is for adults with multiple myeloma who have had 1–3 prior treatments and are lenalidomide‑refractory.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Florence · NCT06933277

• Real-world outcomes for adults with AML treated with new drugs (BoxTrial)

  This project will follow adults with AML treated in routine care across Italy to see how new approved drugs and combinations perform over at least two years.

  Recruiting at 2 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · San Giovanni Rotondo and 1 other locations · NCT06513273

• Potential of asciminib in early chronic‑phase CML

  This trial will see if asciminib alone, or asciminib plus nilotinib, helps adults newly diagnosed with chronic‑phase, BCR‑ABL–positive CML reach deep molecular responses and remain off treatment.

  Recruiting at 11 sites Phase 2 Gruppo Italiano Malattie EMatologiche dell'Adulto · Barcelona and 10 other locations · NCT06409936

• Mapping antithrombotic regimens in Multiple Myeloma patients

  This study looks at how different blood-thinning treatments help prevent blood clots in people with Multiple Myeloma over three years.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma · NCT06028087

• Characterizing genetic and protein changes in adult AML patients with specific rearrangements

  This study is trying to learn more about the genetic and protein changes in adults with a specific type of acute myeloid leukemia to improve understanding and treatment options.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Piacenza · NCT05839392

• Characterizing biological aspects of untreated ITP patients

  This study is trying to learn more about untreated primary Immune Thrombocytopenia (ITP) by looking at blood and other samples from patients who are starting their first treatment to see how their condition changes over time.

  Recruiting at 5 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · Bologna and 4 other locations · NCT05694325

• Using ibrutinib to treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia

  This study is testing if the drug ibrutinib can help adults with chronic lymphocytic leukemia who also have autoimmune hemolytic anemia feel better.

  Recruiting at 3 sites Phase 2 Gruppo Italiano Malattie EMatologiche dell'Adulto · Florence and 2 other locations · NCT05694312

• Collecting data on Chronic Lymphocytic Leukemia in Italy

  This study is collecting information from patients newly diagnosed with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B-Cell Lymphocytosis in Italy to better understand these conditions.

  Recruiting at 24 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · Alessandria and 23 other locations · NCT04867915

• Using stem cell transplantation for high-risk MDS patients

  This study is testing whether a stem cell transplant right away or after treatment with a specific drug is better for people with high-risk myelodysplastic syndromes.

  Recruiting at 46 sites Phase 3 Gruppo Italiano Malattie EMatologiche dell'Adulto · Alessandria and 45 other locations · NCT04184505

• Using Gemtuzumab with Chemotherapy for Treating Acute Myeloid Leukemia

  This study tests if adding a drug called gemtuzumab to regular chemotherapy can help people with certain types of acute myeloid leukemia have better treatment results and lower disease levels after their initial treatment.

  Recruiting at 48 sites Phase 3 Gruppo Italiano Malattie EMatologiche dell'Adulto · Alessandria and 47 other locations · NCT04168502

Quick answers

How many clinical trials run by Gruppo Italiano Malattie EMatologiche dell'Adulto are recruiting right now?

12, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in Italy (11 trials), Spain (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →